As Co-founder and Chief Executive Officer of Nanoscope Therapeutics, Sulagna Bhattacharya leads a talented and diverse team dedicated to the development of sight-restoring therapies for the millions of patients worldwide blinded by inherited retinal diseases for which no cure exists. Ms. Bhattacharya is a serial entrepreneur having co-founded several biotech and biomedical device/diagnostic companies. Before entering the biotechnology world, Ms. Bhattacharya had decades of experience in management consulting at Deloitte and Hitachi Consulting. Her specialties included business intelligence and risk management. She played a key role in seven full life cycle project implementations including multi-billion-dollar mergers and acquisitions and later founded a Management Consulting Company. Currently, Ms. Bhattacharya sits on the Board of Directors of the Biotechnology Innovation Organization (BIO) where she serves on the Health Section Governing Board, and the Emerging Companies Section Governing Board. She also serves on multiple committees including the Capital Formation Committee, and the Corporate Governance Committee. She is also serving as an Entrepreneur-in-Residence at the University of Texas Southwestern Medical School.